BACKGROUND: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. METHODS: Triapine 105 mg/m(2) IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m(2) on days 1, 8, and 15, of a 28 day cycle. RESULTS: Eighteen patients enrolled. Three patients were not eligible due to protocol violations. No objective antitumor responses were seen. Three patients (20%) experienced stable disease (90% CI 5.7-44%). Median overall survival: 5.4 months (95% CI 4.2-11.6 months); median time to progression: 1.8 months (95% CI 1.7-3.5 months). Five patients developed acute infusion reactions to Triapine related to elevated methemoglobinemia. Patients with MDR1 variant genotypes of C3435T experienced superior overall survival compared to non-variants (13.3 vs. 4.3 months, respectively, p = 0.023). CONCLUSION: This regimen did not demonstrate activity in relapsed NSCLC. Prolonged survival seen with MDR1 variant genotypes is hypothesis-generating.
BACKGROUND: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. METHODS:Triapine 105 mg/m(2) IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m(2) on days 1, 8, and 15, of a 28 day cycle. RESULTS: Eighteen patients enrolled. Three patients were not eligible due to protocol violations. No objective antitumor responses were seen. Three patients (20%) experienced stable disease (90% CI 5.7-44%). Median overall survival: 5.4 months (95% CI 4.2-11.6 months); median time to progression: 1.8 months (95% CI 1.7-3.5 months). Five patients developed acute infusion reactions to Triapine related to elevated methemoglobinemia. Patients with MDR1 variant genotypes of C3435T experienced superior overall survival compared to non-variants (13.3 vs. 4.3 months, respectively, p = 0.023). CONCLUSION: This regimen did not demonstrate activity in relapsed NSCLC. Prolonged survival seen with MDR1 variant genotypes is hypothesis-generating.
Authors: Brigette Ma; Boon Cher Goh; Eng Huat Tan; Kwok Chi Lam; Ross Soo; Swan Swan Leong; Ling Zhi Wang; Frankie Mo; Anthony T C Chan; Benny Zee; Tony Mok Journal: Invest New Drugs Date: 2007-09-12 Impact factor: 3.850
Authors: Charles M Rudin; Wanqing Liu; Apurva Desai; Theodore Karrison; Xuemin Jiang; Linda Janisch; Soma Das; Jacqueline Ramirez; Balasubramanian Poonkuzhali; Erin Schuetz; Donna Lee Fackenthal; Peixian Chen; Deborah K Armstrong; Julie R Brahmer; Gini F Fleming; Everett E Vokes; Michael A Carducci; Mark J Ratain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: J Souglakos; I Boukovinas; M Taron; P Mendez; D Mavroudis; M Tripaki; D Hatzidaki; A Koutsopoulos; E Stathopoulos; V Georgoulias; R Rosell Journal: Br J Cancer Date: 2008-04-15 Impact factor: 7.640
Authors: Jill Kolesar; Richard C Brundage; Marcia Pomplun; Dona Alberti; Kyle Holen; Anne Traynor; Percy Ivy; George Wilding Journal: Cancer Chemother Pharmacol Date: 2010-05-04 Impact factor: 3.333
Authors: Suzy V Torti; David H Manz; Bibbin T Paul; Nicole Blanchette-Farra; Frank M Torti Journal: Annu Rev Nutr Date: 2018-08-21 Impact factor: 11.848
Authors: Joseph Chao; Timothy W Synold; Robert J Morgan; Charles Kunos; Jeff Longmate; Heinz-Josef Lenz; Dean Lim; Stephen Shibata; Vincent Chung; Ronald G Stoller; Chandra P Belani; David R Gandara; Mark McNamara; Barbara J Gitlitz; Derick H Lau; Suresh S Ramalingam; Angela Davies; Igor Espinoza-Delgado; Edward M Newman; Yun Yen Journal: Cancer Chemother Pharmacol Date: 2011-11-22 Impact factor: 3.333
Authors: Jill M Kolesar; Kamakshi Sachidanandam; William R Schelman; Jens Eickhoff; Kyle D Holen; Anne M Traynor; Dona B Alberti; James P Thomas; Christopher R Chitambar; George Wilding; William E Antholine Journal: Exp Ther Med Date: 2011-01 Impact factor: 2.447
Authors: Maram T Basha; Carlos Rodríguez; Des R Richardson; Manuel Martínez; Paul V Bernhardt Journal: J Biol Inorg Chem Date: 2013-12-08 Impact factor: 3.358
Authors: Anand Joshi; Brian F Kiesel; Nupur Chaphekar; Reyna Jones; Jianxia Guo; Charles A Kunos; Sarah Taylor; Edward Chu; Raman Venkataramanan; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2020-09-28 Impact factor: 3.333
Authors: Mikael Crona; Paula Codó; Venkateswara Rao Jonna; Anders Hofer; Aristi P Fernandes; Fredrik Tholander Journal: Mol Oncol Date: 2016-07-26 Impact factor: 6.603